Disease-modifying anti-rheumatic drugs (DMARDs) for Sjogren’s syndrome
- 10 May 2021
- journal article
- research article
- Published by Wiley in Emergencias
- Vol. 2021 (5)
- https://doi.org/10.1002/14651858.cd014529
Abstract
Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of DMARDs in the treatment of Sjögren’s syndrome.Keywords
This publication has 31 references indexed in Scilit:
- Epidemiological profile and north–south gradient driving baseline systemic involvement of primary Sjögren’s syndromeRheumatology, 2019
- Sjögren syndromeNature Reviews Disease Primers, 2016
- Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patientsAnnals Of The Rheumatic Diseases, 2014
- Primary Sjögren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patientsRheumatology, 2013
- Updated Method Guidelines for Cochrane Musculoskeletal Group Systematic Reviews and MetaanalysesThe Journal of Rheumatology, 2013
- Estimating Indirect Costs in Primary Sjögren’s SyndromeThe Journal of Rheumatology, 2010
- Oral involvement in primary Sjögren syndromeThe Journal of the American Dental Association, 2008
- A Child With Primary Sjögren Syndrome and a Review of the LiteratureClinical Pediatrics, 2007
- Direct healthcare costs and predictors of costs in patients with primary Sjogren's syndromeRheumatology, 2007
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986